As provinces across Canada begin to roll out third doses of COVID-19 vaccines, information about who qualifies for additional or booster doses is coming at us faster than you can say immunocompromised. But are we immunocompromised? Do we need a booster or a third dose? Is there a difference? Where can we find information tailored for people living with HIV?
Nobody can have missed the fact that a new type of vaccine has had tremendous success against SARS-CoV-2, the virus that causes COVID-19.
Just like across Canada, the number of overdoses continues to climb in Alberta because of a toxic drug supply, worsened by the COVID-19 pandemic that has interrupted the supply of drugs. In Alberta, drug toxicity deaths have been devastating to people with lived or living experience of substance use, as well as their friends and families. In the province alone, we have seen 1,334 fatal overdoses in 2020. We mourn each person lost.
In 2020, Health Canada started to hold consultation meetings with key stakeholders to review federal regulations governing overdose prevention sites (OPS) and supervised consumption sites (SCS). While multiple recommendations and suggestions were brought forward, one that was repeatedly identified by people who use drugs and other stakeholders as being of top concern was the inability to split and share drugs within OPS/SCS settings.
British Columbia is the first province or territory in Canada to recommend one-time birth cohort screening for hepatitis C among people born from 1945 to 1965. This birth cohort has been identified as a key population that needs to be engaged into hepatitis C virus (HCV) care to reduce liver disease complications for several reasons: there are many undiagnosed cases of hepatitis C, they account for nearly 60% of positive hepatitis C results in B.C., and many people in this cohort have not received confirmatory HCV RNA testing.
In Canada, one in three people affected by hepatitis C was born outside of the country. Hepatitis C prevalence among Canadian immigrants and newcomers is double the overall Canadian prevalence. Research also shows that immigrants and newcomers experience worse health outcomes from viral hepatitis and liver cancer when compared to the Canadian-born population, including higher rates of hepatocellular carcinoma and mortality rates from viral hepatitis and liver cancer that are two to four times higher. Talking to Canadian immigrants about hepatitis C becomes very important given the fact that they are a population at risk of disease.
